MOR00208: Phase I/IIa final data

Final data from 27 evaluable high-risk, heavily pretreated relapsed or refractory CLL or SLL patients in a Phase I/IIa trial showed that 0.3-12 mg/kg doses of IV MOR208 led to a median progression-fre...